NasdaqGS:OSUR

Stock Analysis Report

Executive Summary

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally.


Snowflake Analysis

Flawless balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has OraSure Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OSUR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.1%

OSUR

-7.5%

US Medical Equipment

-7.6%

US Market


1 Year Return

-43.6%

OSUR

10.7%

US Medical Equipment

10.2%

US Market

Return vs Industry: OSUR underperformed the US Medical Equipment industry which returned 12.7% over the past year.

Return vs Market: OSUR underperformed the US Market which returned 10.5% over the past year.


Shareholder returns

OSURIndustryMarket
7 Day-1.1%-7.5%-7.6%
30 Day-20.8%-6.6%-4.5%
90 Day-25.2%-2.3%-0.6%
1 Year-43.6%-43.6%11.6%10.7%12.5%10.2%
3 Year-48.8%-48.8%64.4%59.8%37.1%28.3%
5 Year-14.8%-14.8%98.6%77.8%60.8%43.2%

Price Volatility Vs. Market

How volatile is OraSure Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OraSure Technologies undervalued compared to its fair value and its price relative to the market?

22.44x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: OSUR ($6.05) is trading above our estimate of fair value ($0.35)

Significantly Below Fair Value: OSUR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: OSUR is good value based on its PE Ratio (22.4x) compared to the Medical Equipment industry average (44.9x).

PE vs Market: OSUR is poor value based on its PE Ratio (22.4x) compared to the US market (17.2x).


Price to Earnings Growth Ratio

PEG Ratio: OSUR's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: OSUR is good value based on its PB Ratio (1.2x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is OraSure Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-139.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OSUR's earnings are forecast to decline over the next 3 years (-139.7% per year).

Earnings vs Market: OSUR's earnings are forecast to decline over the next 3 years (-139.7% per year).

High Growth Earnings: OSUR's earnings are forecast to decline over the next 3 years.

Revenue vs Market: OSUR's revenue (1.8% per year) is forecast to grow slower than the US market (7.6% per year).

High Growth Revenue: OSUR's revenue (1.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OSUR is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has OraSure Technologies performed over the past 5 years?

26.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OSUR has a large one-off gain of $10.8M impacting its December 31 2019 financial results.

Growing Profit Margin: OSUR's current net profit margins (10.8%) are lower than last year (11.3%).


Past Earnings Growth Analysis

Earnings Trend: OSUR has become profitable over the past 5 years, growing earnings by 26.5% per year.

Accelerating Growth: OSUR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: OSUR had negative earnings growth (-18.3%) over the past year, making it difficult to compare to the Medical Equipment industry average (1.7%).


Return on Equity

High ROE: OSUR's Return on Equity (5.4%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is OraSure Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: OSUR's short term assets ($224.6M) exceed its short term liabilities ($29.2M).

Long Term Liabilities: OSUR's short term assets ($224.6M) exceed its long term liabilities ($12.9M).


Debt to Equity History and Analysis

Debt Level: OSUR is debt free.

Reducing Debt: OSUR has not had any debt for past 5 years.

Debt Coverage: OSUR has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: OSUR has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: OSUR has a low level of unsold assets or inventory.

Debt Coverage by Assets: OSUR's debt is not covered by short term assets (assets are -187.1x debt).


Next Steps

Dividend

What is OraSure Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%4.0%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate OSUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OSUR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OSUR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OSUR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OSUR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Steve Tang (58yo)

1.8yrs

Tenure

US$2,099,594

Compensation

Dr. Stephen S. Tang, also known as Steve, Ph.D. has been President and Chief Executive Officer at OraSure Technologies, Incorporation since April 01, 2018. Dr. Tang has been Chief Executive Officer and Pre ...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD2.10M) is about average for companies of similar size in the US market ($USD1.73M).

Compensation vs Earnings: Steve's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Stephen Tang
President1.8yrsUS$2.10m0.32% $1.2m
Roberto Cuca
CFO & Principal Accounting Officer1.7yrsUS$1.05m0.15% $561.8k
Jack Jerrett
Senior VP19.3yrsUS$973.46k0.22% $809.1k
Anthony Zezzo
Executive VP & Business Unit Leader of Infectious Disease3.1yrsUS$1.06m0.37% $1.4m
James Rauth
Senior Vice President of Operations0.3yrsno datano data
Jeanne Mell
Vice President of Corporate Communications1.5yrsno datano data
Kathleen Weber
Executive VP & Business Unit Leader of Molecular Solutions7.3yrsno data0.17% $645.7k
David Rappaport
Senior Vice President of Business Development1.8yrsno datano data
Michele Miller
VP of Finance & Controller1.3yrsno data0.024% $90.1k

1.8yrs

Average Tenure

55yo

Average Age

Experienced Management: OSUR's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Stephen Tang
President1.8yrsUS$2.10m0.32% $1.2m
Charles Patrick
Independent Director14.1yrsUS$168.99k0.10% $378.4k
Eamonn Hobbs
Independent Director3.9yrsUS$157.24k0.049% $184.8k
Ronny Lancaster
Independent Director16.8yrsUS$169.74k0.034% $127.4k
Michael Celano
Independent Chairman of the Board1.8yrsUS$506.36k0.10% $379.6k
James Datin
Director0.5yrsno data0.022% $81.4k
Mara Aspinall
Independent Director2.7yrsUS$157.24k0.038% $142.6k
Aradhana Sarin
Independent Director2yrsUS$562.31k0.027% $102.2k

3.3yrs

Average Tenure

59yo

Average Age

Experienced Board: OSUR's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

OraSure Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OraSure Technologies, Inc.
  • Ticker: OSUR
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$374.062m
  • Shares outstanding: 61.73m
  • Website: https://www.orasure.com

Number of Employees


Location

  • OraSure Technologies, Inc.
  • 220 East First Street
  • Bethlehem
  • Pennsylvania
  • 18015
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OSURNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1986
EP3DB (Deutsche Boerse AG)YesCommon StockDEEURNov 1986

Biography

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV–1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/27 01:02
End of Day Share Price2020/02/26 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.